In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease.
View / Open Files
Authors
Publication Date
2021-10-29Journal Title
Sci Adv
ISSN
2375-2548
Publisher
American Association for the Advancement of Science (AAAS)
Volume
7
Issue
44
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Meisl, G., Hidari, E., Allinson, K., Rittman, T., DeVos, S. L., Sanchez, J. S., Xu, C. K., et al. (2021). In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease.. Sci Adv, 7 (44) https://doi.org/10.1126/sciadv.abh1448
Abstract
Both the replication of protein aggregates and their spreading throughout the brain are implicated in the progression of Alzheimer’s disease (AD). However, the rates of these processes are unknown and the identity of the rate-determining process in humans has therefore remained elusive. By bringing together chemical kinetics with measurements of tau seeds and aggregates across brain regions, we can quantify their replication rate in human brains. Notably, we obtain comparable rates in several different datasets, with five different methods of tau quantification, from postmortem seed amplification assays to tau PET studies in living individuals. Our results suggest that from Braak stage III onward, local replication, rather than spreading between brain regions, is the main process controlling the overall rate of accumulation of tau in neocortical regions. The number of seeds doubles only every ∼5 years. Thus, limiting local replication likely constitutes the most promising strategy to control tau accumulation during AD.
Keywords
Brain Disorders, Dementia, Aging, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Alzheimer's Disease, Acquired Cognitive Impairment, Neurodegenerative, Neurosciences, Neurological
Sponsorship
We acknowledge funding
from Sidney Sussex College Cambridge (GM) and the European Research Council Grant Number
669237 (to D.K.) and the Royal Society (to D.K.). The Cambridge Brain Bank is supported
by the NIHR Cambridge Biomedical Research Centre.
Funder references
European Research Council (669237)
Wellcome Trust (103838/Z/14/Z)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
National Institute for Health Research (IS-BRC-1215-20014)
Medical Research Council (MR/M009041/1)
Identifiers
PMC8555892, 34714685
External DOI: https://doi.org/10.1126/sciadv.abh1448
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332216
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk